Goldman Sachs Group Inc Phathom Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

  • $596 Billion
  • Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 187,874 shares of PHAT stock, worth $813,494. This represents 0.0% of its overall portfolio holdings.

Number of Shares
187,874
Previous 187,874 -0.0%
Holding current value
$813,494
Previous $1.18 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 09, 2025
SELL
$4.22 - $7.74 $946,917 - $1.74 Million
-224,388 Reduced 54.43%
187,874 $1.18 Million
Q4 2024

Feb 11, 2025
SELL
$7.45 - $18.94 $163,594 - $415,903
-21,959 Reduced 5.06%
412,262 $3.35 Million
Q3 2024

Nov 14, 2024
BUY
$10.25 - $19.5 $173,604 - $330,271
16,937 Added 4.06%
434,221 $7.85 Million
Q2 2024

Aug 13, 2024
BUY
$8.97 - $12.05 $1.88 Million - $2.53 Million
209,912 Added 101.22%
417,284 $4.3 Million
Q1 2024

May 15, 2024
SELL
$6.21 - $11.05 $17,630 - $31,370
-2,839 Reduced 1.35%
207,372 $2.2 Million
Q4 2023

Feb 13, 2024
BUY
$6.99 - $10.71 $501,259 - $768,024
71,711 Added 51.78%
210,211 $1.92 Million
Q3 2023

May 14, 2024
SELL
$10.26 - $15.7 $735,754 - $1.13 Million
-71,711 Reduced 34.11%
138,500 $1.44 Million
Q3 2023

Nov 14, 2023
SELL
$10.26 - $15.7 $165,883 - $253,837
-16,168 Reduced 10.45%
138,500 $1.44 Million
Q2 2023

May 14, 2024
BUY
$7.28 - $14.32 $771,585 - $1.52 Million
105,987 Added 217.72%
154,668 $2.21 Million
Q2 2023

Aug 14, 2023
BUY
$7.28 - $14.32 $771,585 - $1.52 Million
105,987 Added 217.72%
154,668 $2.21 Million
Q1 2023

May 14, 2024
SELL
$6.19 - $12.36 $156,798 - $313,091
-25,331 Reduced 34.23%
48,681 $347,000
Q1 2023

May 11, 2023
SELL
$6.19 - $12.36 $156,798 - $313,091
-25,331 Reduced 34.23%
48,681 $347,000
Q4 2022

May 14, 2024
BUY
$9.18 - $11.53 $153,030 - $192,205
16,670 Added 29.07%
74,012 $830,000
Q4 2022

Feb 13, 2023
BUY
$9.18 - $11.53 $153,030 - $192,205
16,670 Added 29.07%
74,012 $830,000
Q3 2022

May 14, 2024
BUY
$6.46 - $12.11 $32,106 - $60,186
4,970 Added 9.49%
57,342 $635,000
Q3 2022

Nov 10, 2022
BUY
$6.46 - $12.11 $32,106 - $60,186
4,970 Added 9.49%
57,342 $635,000
Q2 2022

May 14, 2024
SELL
$6.2 - $15.5 $978,601 - $2.45 Million
-157,839 Reduced 75.09%
52,372 $442,000
Q2 2022

Aug 15, 2022
BUY
$6.2 - $15.5 $149,017 - $372,542
24,035 Added 84.82%
52,372 $442,000
Q1 2022

May 16, 2022
SELL
$11.55 - $20.06 $66,759 - $115,946
-5,780 Reduced 16.94%
28,337 $386,000
Q4 2021

Feb 14, 2022
BUY
$17.83 - $33.15 $480,589 - $893,525
26,954 Added 376.29%
34,117 $671,000
Q3 2021

Nov 10, 2021
BUY
$30.69 - $36.83 $219,832 - $263,813
7,163 New
7,163 $230,000

Others Institutions Holding PHAT

# of Institutions
152
Shares Held
66.6M
Call Options Held
94K
Put Options Held
55.5K
View Full List

About Phathom Pharmaceuticals, Inc.

PHAT Quotes by TradingView
  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $170M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email